BORDEAUX, France, September 10, 2014 /PRNewswire/ --
Europlasma, a world-known French manufacturer providing
solutions for the production of renewable energy and the recovery
of hazardous waste, today announced that its shares will resume
trading on Alternext Paris (ISIN code: FR0000044810). The Group is
ready to consolidate its business development and will soon launch
a capital increase to bolster its financial capacity.
Having focused on its core business since end-2013, the Group
has from January 2014 completed its
restructuring, and under the leadership of the new Managing
Director, Mr. Jean-Eric Petit, has
implemented a transparent strategy based on commercial deployment
of its proprietary technologies.
The CHO Morcenx renewable energy power plant has seen great
technical progress, and last June the company announced its
preliminary acceptance and the implementation of a technical
programme, punctuated with testing milestones, aimed at ramping up
the plant in preparation for the final acceptance date in early
2015. In this context, the performance tests completed in July with
engines confirmed the increase of the electrical output (from 3 to
4MWe). This improvement needs to be validated by an endurance test
this is the objective of the September campaign.
At the same time, technical changes to the operation of the
asbestos treatment plant (Inertam) have led to significant
improvements in its performance. Lastly, several orders were placed
for plasma solution studies, reflecting both global interest in
this technology and recognition of Europlasma's expertise.
Europlasma now masters particularly innovative patented
technologies whose applications address current environmental
challenges and whose markets are driven by favourable regulatory
changes.
Europlasma is preparing a capital increase with preferential
subscription rights (PSR) of around euros 22
million which it intends to launch in September. The aim of
this capital increase, subject to a visa from the French Financial
Authorities (AMF), is to:
i) improve the Group's current financial gearing by repaying
and/or converting the bridge loans granted by its main financial
partners since late 2012;
ii) fund the reinvestment into the CHO Morcenx plant required to
improve its performance and to provide working capital during the
ramp-up period;
ii) finalize the Group's recovery and enable it to capture the
growth opportunities available within each of its business
segments.
Within this context, everything is in place to resume the
trading of Europlasma shares from Tuesday, 9
September 2014 at 9 a.m.
under normal market conditions.
The final terms for the capital increase are currently being
approved and should be disclosed shortly. Europlasma has decided to
protect the interests of its shareholders by preserving their PSRs.
Furthermore, Europlasma will issue upon closing of the capital
increase redeemable share purchase warrants (BSAR warrants)
allocated free of charge to all shareholders whose shares have been
recorded at a date to be communicated upon launching the capital
increase, whether or not they have subscribed for the capital
increase. These BSAR warrants will be listed. They will enable
bearers to participate fully in the future value creation of the
Europlasma group.
The specific terms and timetable of the capital increase will be
covered in a press release and set out in the prospectus.
About Europlasma
Europlasma is a French group specialised in clean technologies
and the production of renewable energy. Founded in 1992 to apply
its proprietary plasma torch technology to the destruction and
recovery of hazardous waste, the Europlasma Group now comprises
three divisions:
- Europlasma is a global player in the field of plasma
torch systems and related applications;
- Inertam is the global expert in the disposal of asbestos
waste and hazardous waste;
- CHO Power produces energy through the gasification of
waste and biomass.
http://www.europlasma.com [Alternext - NYSE
Euronext Paris - Ticker: ALEUP - ISIN: FR0000044810]
Contacts
EUROPLASMA
Anne Borderes - Shareholder & investor relations -
+33(0)5-56-49-70-00 - contactbourse@europlasma.com
CAPVALUE
Samuel Beaupain - Press
relations - +33(0)1-80-81-50-05 -sbeaupain@capvalue.fr